Abstract 2106P
Background
Vaccination against SARS-CoV-2 reduces morbidity from COVID-19 infection in patients (pts) with cancer. Hesitancy toward vaccination remains in some groups. Ongoing vaccinations are recommended for vulnerable pts. This study provides detailed patient-reported and safety outcomes, providing information for patients and clinicians regarding vaccination safety.
Methods
SerOzNET is a prospective study of pts with cancer who received COVID-19 vaccination (BNT162b2, mRNA1273 or ChadOx1-S) in 2021-22 in 3 cohorts: children (5-11 years(y)), adolescents (12-19y) and adults. From pre-vaccination (to 1 month post dose 3, pts completed serial electronic surveys: Oxford COVID-19 Vaccine Confidence and Complacency Scale, patient reported adverse events (AE), and quality of life (5-19y: PedsQL; 20+:QLQC30). Physicians reported safety, including serious adverse events and thrombosis.
Results
511 pts were enrolled (40 children, 74 adolescents, 397 adults); 499 had one or more patient or medical outcome report completed. Median age was 52 (range 5-85). Pain at injection site was the commonest AE (60-90% of pts). AEs reported in 20-50% of all pts after dose 1, 2 or 3 were fatigue, muscle pain and fever. Headache was more common in adolescents and adults (18-26%) than children (0-11%). Chills were more common in children and adolescents (11-29%) than adults (12-19%). Delays/modifications to cancer treatment from dose 1 to 1 month post dose 2 were reported in 33% of children, 27% of adolescents and 21% of adults; and from dose 3 to 1 month post dose 3 in 10% of children, 18% of adolescents and 12% of adults. None were attributed to vaccine toxicity. Venous thromboembolic events (VTE) were reported in 4/397 adults; there were no arterial events, and no thrombotic events in children or adolescents. No allergic reactions were reported. Mean QLQC30 in adults, and PedsQL in pts <20y was similar pre and post dose 1 (p=n.s. all ages) and 2 (p=n.s. children, adults. Adolescents: 2% improvement, p=0.006).
Conclusions
This large trial dataset demonstrates SARS-CoV-2 vaccination in pts with cancer has manageable toxicity. VTE was low, consistent with background rates. Individuals with cancer can be reassured that SARS-CoV-2 vaccination is safe and will not disrupt their cancer therapy.
Clinical trial identification
ACTRN12621001004853.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Cancer Australia (Australian Government), Victorian Cancer Agency (Victorian Government, Australia), Leukaemia Foundation Australia.
Disclosure
E.S. Ahern: Financial Interests, Institutional, Funding, Research funding: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
2126P - Exercise implementation into a clinic setting with 1.660 cancer patients: Real-world data from eight years oncological exercise therapy in Cologne (OTT)
Presenter: Timo Niels
Session: Poster session 06
2127P - Long-term yoga reduces the side effects of systemic therapies and improves arm symptoms in the breast cancer patients
Presenter: Mayank Jain
Session: Poster session 06
2128P - exerCise discussion with Oncologist duriNg caNcEr ConsultaTion: The CONNECT study
Presenter: Sara Pilotto
Session: Poster session 06
2129P - Feasibility of a virtual exercise program to mitigate decline in physical function for advanced lung cancer patients
Presenter: Ying Wang, Sarah Yeo
Session: Poster session 06